MeMed News Archive

Maccabi Healthcare Services Announces it is the First HMO in the World to Include MeMed BV® Test as Part of Routine Care

07 Jun 2022

DiaSorin receives FDA 510(K) clearance for Its LIAISON MeMed BV test

25 Jul 2022

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio

10 Jan 2022

Maimonides Medical Center adopts revolutionary technology that quickly distinguishes bacterial and viral Infections

22 Mar 2022

After a decade and 130 million dollars, the MeMed test receives FDA clearance

27 Oct 2021

2021 Dun & Bradstreet’s Best Companies to Work For

31 Dec 2021

Platform distinguishing between viral and bacterial infections cleared by FDA

28 Sep 2021

FDA Clears New Technology to Differentiate Bacterial, Viral Infections Using Biomarkers

28 Sep 2021

Bacterial and Viral Biomarker Test Gains US FDA Clearance

27 Sep 2021

MeMed Gets FDA 510(k) Clearance for Test Distinguishing Between Viral, Bacterial Infections

27 Sep 2021

Israel’s MeMed gets FDA approval for ‘breakthrough’ infection test

26 Sep 2021

MeMed Received FDA Clearance for Infection Test

26 Sep 2021

FDA clears MeMed’s point-of-need infectious disease test

26 Sep 2021

US approves MeMed test to distinguish bacterial from viral infections

26 Sep 2021

MeMed’s Diagnostics, BV Test and Key Platform Get 510(k) Clearance

26 Sep 2021

Rapid test to distinguish bacterial and viral infections wins US approval

20 Sep 2021

Pioneering test which can indicate COVID-19 severity receives CE Mark

12 Sep 2021

COVID-19 severity test is approved for sale in the UK

11 Sep 2021

Longitude Prize: Bacterial or Viral: To Treat or Not to Treat with Antibiotics

04 Sep 2017

Test predicting COVID-19 severity receives CE mark

27 Jul 2021

MeMed’s Covid-19 severity test receives its CE Mark to predict severe outcomes

27 Jul 2021

MeMed Wins $4.1M DOD Grant toward Manufacturing of POC Platform

16 Feb 2018

MeMed Receives CE Mark for Diagnostic Platform & Infection Assay

04 Jun 2021

MeMed’s co-founder and CEO, Dr. Eran Eden on the BioBoss Podcast

25 Sep 2020

Israeli firm advances diagnostic solutions for Covid-19

07 Jul 2020

Interview with Eran Eden, MeMed’s CEO

27 Mar 2020

Israeli Startups Join The Fight Against Coronavirus

18 Mar 2020

OurCrowd Portfolio Companies Pivot to Tackle Coronavirus Pandemic

07 Mar 2020

Technology Pioneers 2019

27 Apr 2019

Rapid blood test to ‘cut antibiotic use’

27 Mar 2015

A New Blood Test Could Stop Doctors From Overprescribing Antibiotics

17 Sep 2013

News

Maccabi Healthcare Services Announces it is the First HMO in the World to Include MeMed BV® Test as Part of Routine Care

DiaSorin receives FDA 510(K) clearance for Its LIAISON MeMed BV test

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio

Maimonides Medical Center adopts revolutionary technology that quickly distinguishes bacterial and viral Infections

After a decade and 130 million dollars, the MeMed test receives FDA clearance

2021 Dun & Bradstreet’s Best Companies to Work For

Platform distinguishing between viral and bacterial infections cleared by FDA

FDA Clears New Technology to Differentiate Bacterial, Viral Infections Using Biomarkers

Bacterial and Viral Biomarker Test Gains US FDA Clearance

MeMed Gets FDA 510(k) Clearance for Test Distinguishing Between Viral, Bacterial Infections

Israel’s MeMed gets FDA approval for ‘breakthrough’ infection test

MeMed Received FDA Clearance for Infection Test

FDA clears MeMed’s point-of-need infectious disease test

US approves MeMed test to distinguish bacterial from viral infections

MeMed’s Diagnostics, BV Test and Key Platform Get 510(k) Clearance

Rapid test to distinguish bacterial and viral infections wins US approval

Pioneering test which can indicate COVID-19 severity receives CE Mark

COVID-19 severity test is approved for sale in the UK

Longitude Prize: Bacterial or Viral: To Treat or Not to Treat with Antibiotics

Test predicting COVID-19 severity receives CE mark

MeMed’s Covid-19 severity test receives its CE Mark to predict severe outcomes

MeMed Wins $4.1M DOD Grant toward Manufacturing of POC Platform

MeMed Receives CE Mark for Diagnostic Platform & Infection Assay

MeMed’s co-founder and CEO, Dr. Eran Eden on the BioBoss Podcast

Israeli firm advances diagnostic solutions for Covid-19

Interview with Eran Eden, MeMed’s CEO

Israeli Startups Join The Fight Against Coronavirus

OurCrowd Portfolio Companies Pivot to Tackle Coronavirus Pandemic

Technology Pioneers 2019

Rapid blood test to ‘cut antibiotic use’

A New Blood Test Could Stop Doctors From Overprescribing Antibiotics

Contact Us

Thank you!